Author: Katrina Megget

Johnson & Johnson’s Remicade (infliximab) has been shown to control Crohn’s disease more effectively than standard immunomodulator azathioprine, the company says.

Roche’s therapeutic antibody MabThera/Rituxan (rituximab) has delayed disease progression in patients with a form of leukaemia, the drug giant says.

Genentech and OSI Pharmaceuticals have announced the combination treatment of Avastin (bevacizumab) with Tarceva (erlotinib) has not shown to improve survival in a Phase III study.

Schering-Plough is planning to slash its US sales workforce by 20% in a bid to compensate for falling prescriptions of its drugs.

The UK’s version of a digital archive of peer-reviewed research papers will be further developed after getting a cash injection of £1.3 million.